AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | -- |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 22.660/2.660 |
| EBITDA (in USD) | -98.843M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -74.15 |
| Total Assets (in USD) | 71.144M |
|---|---|
| Total Liabilities (in USD) | 20.839M |
| Revenue TTM (in USD) | 1.054M |
| Cash (in USD) | 34.863M |
| Market Cap (in USD) | 48.628 M |
| Revenue Per Share TTM | 0.269 |
| Gross Profit TTM (in USD) | -0.262M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Aeglea Bio Therapeutics Inc
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Employees: 69
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Leslie S. Sloan Ph.D. | Chief Operating Officer | 1971 |
| 2. | Mr. Michael C. Hanley M.B.A. | Chief Commercial Officer & Chief Bus. Officer | 1973 |
| 3. | Mr. Jeffrey M. Goldberg | Pres, CEO & Director | 1973 |
| 4. | Mr. Jonathan D. Alspaugh M.B.A. | CFO & Principal Accounting Officer | 1983 |
| 5. | Ms. Cortney Caudill M.B.A. | Sr. VP of Technical Operations | NA |
| 6. | Joey Perrone | VP of Fin. & Investor Relations | NA |
| 7. | Mr. James Paul Kastenmayer J.D., Ph.D. | Gen. Counsel & Corp. Sec. | 1972 |
| 8. | Dr. Kelly Boothe Ph.D. | Sr. Director of Corp. Communications & Investor Relations | NA |
| 9. | Dr. Josie Gayton Ph.D. | Sr. VP of Program Strategy, Operations & Chief of Staff | NA |
| 10. | Dr. Linda Neuman M.D., MBA | Chief Medical Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-3.600 5.090% | 68.86 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-2.680 3.811% | 68.6 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-5.190 1.153% | 450.48 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-0.570 0.109% | 521.4 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -83.951M | -65.66M | -80.893M | -78.254M | -44.348M |
| Minority Interest | - | - | - | - | - |
| Net Income | -83.815M | -65.801M | -80.3M | -75.693M | -44.348M |
| Selling General Administrative | 28.531M | 27.319M | 21.843M | 15.734M | 12.632M |
| Gross Profit | 2.329M | 18.739M | 0.022M | -64.6M | 3.888M |
| Reconciled Depreciation | 1.567M | 1.576M | 0.996M | 0.418M | 0.293M |
| Ebit | -86.348M | -67.225M | -81.481M | -80.752M | -44.348M |
| Ebitda | -84.781M | -65.649M | -80.485M | -80.334M | -44.055M |
| Depreciation And Amortization | 1.567M | 1.576M | 0.996M | 0.418M | 0.293M |
| Operating Income | -84.781M | -65.649M | -81.481M | -80.334M | -45.463M |
| Other Operating Expenses | 87.11M | 84.388M | 81.481M | 80.334M | 49.351M |
| Interest Expense | 0.837M | 1.565M | 0.593M | 0M | 0M |
| Tax Provision | -0.136M | 0.141M | - | - | - |
| Interest Income | 0.837M | 0.111M | 0.593M | 2.143M | 1.172M |
| Net Interest Income | 0.837M | 0.111M | 0.593M | 2.143M | 1.172M |
| Income Tax Expense | -0.136M | 0.141M | -0.593M | -2.561M | -0.057M |
| Total Revenue | 2.329M | 18.739M | 0.022M | 0M | 3.888M |
| Total Operating Expenses | 87.11M | 84.388M | 81.481M | 80.334M | 49.351M |
| Cost Of Revenue | - | - | - | 64.6M | 36.719M |
| Total Other Income Expense Net | 0.83M | -0.011M | 0.588M | 2.08M | -0.057M |
| Net Income From Continuing Ops | -83.815M | -65.801M | -80.893M | -78.254M | -44.348M |
| Net Income Applicable To Common Shares | -83.815M | -65.801M | -80.893M | -78.254M | -44.348M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Total Assets | 71.144M | 109.926M | 161.618M | 83.183M | 77.739M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 6.172M | 5.763M | 3.516M | 2.556M | 2.158M |
| Total Liab | 20.839M | 25.985M | 21.786M | 23.102M | 10.311M |
| Total Stockholder Equity | 50.305M | 83.941M | 139.832M | 60.081M | 67.428M |
| Other Current Liab | 12.837M | 14.03M | 0.464M | 0.469M | 9.576M |
| Common Stock | 0.006M | 0.005M | 0.005M | 0.003M | 0.002M |
| Capital Stock | 0.006M | 0.005M | 0.005M | 0.003M | 0.002M |
| Retained Earnings | -425.624M | -341.809M | -276.008M | -195.115M | -116.861M |
| Good Will | - | - | - | - | - |
| Other Assets | 1.639M | 1.882M | 1.889M | 1.511M | 0.05M |
| Cash | 34.863M | 15.142M | 90.095M | 19.253M | 22.461M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 14.656M | 20.144M | 16.443M | 18.359M | 10.239M |
| Current Deferred Revenue | 0.517M | 2.359M | 13.406M | 14.385M | - |
| Net Debt | -30.234M | -10.098M | -84.647M | -14.19M | -22.461M |
| Short Term Debt | 0.625M | 0.436M | 0.319M | 0.351M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 4.629M | 5.044M | 5.448M | 5.063M | - |
| Other Stockholder Equity | 475.971M | 425.765M | 415.824M | 255.142M | 184.314M |
| Property Plant Equipment | 7.247M | 4.549M | 9.94M | 7.167M | 1.018M |
| Total Current Assets | 62.258M | 98.891M | 149.789M | 74.505M | 76.671M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 20.848M | 77.986M | 56.178M | 52.696M | 52.052M |
| Net Receivables | 0.375M | 0.815M | - | - | 0M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | -0.815M | - | - | - |
| Accounts Payable | 0.677M | 3.319M | 2.254M | 3.154M | 0.663M |
| Accumulated Other Comprehensive Income | -0.048M | -0.02M | 0.011M | 0.051M | -0.027M |
| Non Currrent Assets Other | 2.236M | 2.68M | 1.957M | 1.567M | 0.05M |
| Non Current Assets Total | 8.886M | 11.035M | 11.829M | 8.678M | 1.068M |
| Capital Lease Obligations | 4.629M | 5.06M | 5.448M | 5.063M | - |
| Long Term Debt Total | - | - | - | 0.031M | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 57.008M | -22.046M | -7.604M | -0.247M | -14.809M |
| Total Cashflows From Investing Activities | 57.008M | -22.619M | -7.604M | -1.739M | -15.231M |
| Total Cash From Financing Activities | 42.678M | 1.393M | 154.512M | 65.723M | 57.068M |
| Net Income | -83.815M | -65.801M | -80.893M | -78.254M | -44.348M |
| Change In Cash | 19.436M | -74.957M | 71.184M | -1.708M | 9.644M |
| Begin Period Cash Flow | 16.98M | 91.937M | 20.753M | 22.461M | 12.817M |
| End Period Cash Flow | 36.416M | 16.98M | 91.937M | 20.753M | 22.461M |
| Total Cash From Operating Activities | -80.144M | -53.716M | -75.775M | -65.692M | -32.193M |
| Depreciation | 1.567M | 1.576M | 0.996M | 0.418M | 0.293M |
| Other Cashflows From Investing Activities | - | - | - | -0.247M | -14.809M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | 3.904M |
| Sale Purchase Of Stock | - | 1.903M | 0.816M | 1.45M | 3.02M |
| Other Cashflows From Financing Activities | 0.222M | 1.903M | 0.816M | 1.45M | 3.02M |
| Capital Expenditures | 0.038M | 0.573M | 4.28M | 1.492M | 0.422M |
| Change In Working Capital | -5.503M | 1.833M | -2.54M | 7.104M | 7.201M |
| Other Non Cash Items | 0.496M | 0.434M | 0.619M | 0.478M | 0.067M |
| Free Cash Flow | -80.182M | -54.289M | -80.055M | -67.184M | -32.615M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Polar Capital Biotech S Inc | 1 year ago | 300000 |
| 2. | BlackRock Extended Mkt Composite | 1 year ago | 88287 |
| 3. | BlackRock Extended Equity Market K | 1 year ago | 77178 |
| 4. | Wellington CIF II SMID Cap Research S3 | 1 year ago | 44795 |
| 5. | Wellington SMID Cap Research Equity | 1 year ago | 44795 |
| 6. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 37379 |
| 7. | Wellington CIF Biotechnology | 1 year ago | 22600 |
| 8. | Wellington CIF Small Cap 2000 | 1 year ago | 22448 |
| 9. | Fidelity® Extended Market Index | 1 year ago | 13497 |
| 10. | Extended Equity Market Fund M | 1 year ago | 9070 |
| 11. | Fidelity® Total Market Index | 1 year ago | 5016 |
| 12. | Northern Trust Wilshire 5000 | 1 year ago | 4704 |
| 13. | Dimensional US Core Equity 2 ETF | 1 year ago | 3762 |
| 14. | Northern Trust Extended Eq Market Idx | 1 year ago | 3262 |
| 15. | NT Ext Equity Mkt Idx Fd - L | 1 year ago | 3262 |
| 16. | Fidelity® Series Total Market Index | 1 year ago | 2967 |
| 17. | NT Ext Equity Mkt Idx Fd - NL | 1 year ago | 1877 |
| 18. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 1 year ago | 1505 |
| 19. | Spartan Total Market Index Pool E | 1 year ago | 1461 |
| 20. | Fidelity Nasdaq Composite Index | 1 year ago | 1372 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | VR Adviser, LLC | 1 year ago | 6343221 |
| 2. | Driehaus Capital Management LLC | 1 year ago | 800853 |
| 3. | Fairmount Funds Management LLC | 1 year ago | 378421 |
| 4. | Polar Capital Holdings PLC | 1 year ago | 300000 |
| 5. | Wellington Management Company LLP | 1 year ago | 299929 |
| 6. | Affinity Asset Advisors, LLC | 1 year ago | 242297 |
| 7. | Logos Global Management LP | 1 year ago | 210000 |
| 8. | EcoR1 Capital, LLC | 1 year ago | 199996 |
| 9. | Suvretta Capital Management, LLC | 1 year ago | 162395 |
| 10. | Rock Springs Capital Management LP | 1 year ago | 136556 |
| 11. | COMMODORE CAPITAL LP | 1 year ago | 116324 |
| 12. | Citadel Advisors Llc | 1 year ago | 97053 |
| 13. | Perceptive Advisors LLC | 1 year ago | 81116 |
| 14. | Aisling Capital Management LP | 1 year ago | 67645 |
| 15. | Millennium Management LLC | 1 year ago | 37813 |
| 16. | Vanguard Group Inc | 1 year ago | 33077 |
| 17. | Geode Capital Management, LLC | 1 year ago | 26800 |
| 18. | Renaissance Technologies Corp | 1 year ago | 23229 |
| 19. | Yu Fan | 1 year ago | 20592 |
| 20. | BlackRock Inc | 1 year ago | 19768 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...